The Hemophilia Management Virtual Summit is supported by independent educational grants from CSL Behring LLC, Baxter Healthcare, and Grifols.
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We research, develop, manufacture and market biotherapies that are used to treat serious and rare conditions. Users of our therapies rely on them for their quality of life and, in many cases, for life itself.
Baxter: A leader in healthcare for more than 80 years. Baxter assists healthcare professionals and their patients with treatment of complex medical conditions, including hemophilia to proactively shape the future of hemophilia treatment by focusing on personalized innovations and solutions.
Grifols is a global healthcare company whose mission is to improve the health and well being of people around the world. We accomplish this mission by producing life-saving protein therapies for patients and by providing hospitals, pharmacies and healthcare professionals with the tools they need to deliver expert medical care.
The Hematologic Malignancies Virtual Summit is supported by independent educational grants from Millennium: The Takeda Oncology Company and Genentech, USA.
Millennium: The Takeda Oncology Company combines the innovative science of a leading American biopharmaceutical company with the global assets – both intellectual and fiscal – of Japan's largest pharmaceutical company.
Genentech uses human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, we are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline.
The Solid Tumor Virtual Summit is supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc. and Lilly USA, LLC.
Boehringer Ingelheim research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need.
Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.
Lilly focuses on speeding innovation and improving outcomes for individual patients, and boasts one of the largest clinical pipelines in the oncology industry.
The Colorectal Cancer Virtual Summit is supported by independent educational grants from Bayer Healthcare Pharmaceuticals Inc., Lilly USA, LLC, Sanofi-Aventis U.S. Inc., and Genentech, USA.
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment.
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of infertility, obstetrics, urology, gastroenterology, endocrinology and osteoarthritis.
For information on becoming a partner email us at firstname.lastname@example.org